Last updated on April 2007

Prophylaxis With Caspofungin in High-Risk Liver Transplantation

Brief description of study

This is a non-comparative, open, multisite prospective estimation study to evaluate the efficacy and safety of caspofungin in the prophylactic treatment of adults who have received an orthotopic liver transplant and are at high risk of developing an invasive fungal infection. It is expected that the proportion of high-risk liver transplant recipients who develop a documented (proven or probable per European Organization for Research and Treatment of Cancer/Mycoses Study Group [EORTC/MSG] modified criteria) invasive fungal infection during the first 100 days after the onset of prophylaxis with caspofungin will be lower than 15%. It is also expected that the incidence of serious drug-related adverse events will be less than 25%.

Clinical Study Identifier: NCT00333645

Find a site near you

Start Over

Complejo Hospitalario Universitario de Santiago

Santiago de Compostela, Spain
  Connect »